INM Key Statistics, Chart & Performance
The current stock price of INM is 1.215 USD. In the past month the price decreased by -20.99%. In the past year, price decreased by -72.81%.
INM Latest News, Press Relases and Analysis
INM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.25 | 1.00T | ||
| JNJ | JOHNSON & JOHNSON | 20.71 | 518.00B | ||
| MRK | MERCK & CO. INC. | 11.41 | 249.49B | ||
| PFE | PFIZER INC | 8.29 | 150.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.31 | 110.92B | ||
| ZTS | ZOETIS INC | 19.09 | 53.33B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.37 | 22.23B | ||
| VTRS | VIATRIS INC | 5.01 | 13.45B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 22.7 | 10.83B | ||
| CORT | CORCEPT THERAPEUTICS INC | 99.17 | 9.18B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.40B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.95B |
Related stock screener links
About INM
Company Profile
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
Company Info
INMED PHARMACEUTICALS INC
1445-885 West Georgia St.
Vancouver BRITISH COLUMBIA V6C1B4 CA
CEO: Eric Adams
Employees: 13
Phone: 16046697207
INMED PHARMACEUTICALS INC / INM FAQ
What does INMED PHARMACEUTICALS INC do?
InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.
What is the stock price of INMED PHARMACEUTICALS INC today?
The current stock price of INM is 1.215 USD. The price decreased by -15.03% in the last trading session.
Does INM stock pay dividends?
INM does not pay a dividend.
What is the ChartMill rating of INMED PHARMACEUTICALS INC stock?
INM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in INMED PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on INM.
What is INMED PHARMACEUTICALS INC worth?
INMED PHARMACEUTICALS INC (INM) has a market capitalization of 3.40M USD. This makes INM a Nano Cap stock.
When does INMED PHARMACEUTICALS INC (INM) report earnings?
INMED PHARMACEUTICALS INC (INM) will report earnings on 2026-02-10.
INM Technical Analysis
INM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to INM. INM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INM Financial Highlights
Over the last trailing twelve months INM reported a non-GAAP Earnings per Share(EPS) of -7.21. The EPS increased by 48.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.46% | ||
| ROE | -70.84% | ||
| Debt/Equity | 0 |